Mouse models dissect the role of p53 in cancer and development

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 337-344

  Lozano, Guillermina ^a   Liu, Geng ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Development; Genetic interactions; Null mice; p53; Tumor models

Indexed keywords

PROTEIN P53;

ANIMAL MODEL; APOPTOSIS; CANCER GENETICS; CANCER MODEL; CARCINOGENESIS; DEVELOPMENT; GROWTH INHIBITION; MOUSE; MOUSE MUTANT; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031987265     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0096     Document Type: Article

References (56)

1. 1. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
2. 2. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
3. 3. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7
4. 4. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, Matsuo I, Ikawa Y, Aizawa S (1993) Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8:3313-3322
5. 5. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. Faseb J 7:938-943
6. 6. Hursting SD, Perkins SN, Phang JM (1994) Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 91:7036-7040
7. 7. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
8. 8. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH (1994) p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9:1767-1773
9. 9. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711
10. 10. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9:882-895
11. 11. Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, Varmus HE, Donehower LA (1997) Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8:829-838
12. 12. Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA, Windle JJ (1997) Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol 17:723-731
13. 13. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646
14. 14. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker ST, Vogelstein B, Friend SH (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781
15. 15. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484
16. 16. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA (1995) Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55:1146-1151
17. 17. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A (1992) Mice deficient for Rb are non-viable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294
18. 18. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of a Rb mutation in the mouse. Nature 359:295-300
19. 19. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, Berns A, te Riele H (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330
20. 20. Kemp CJ, Donehower LA, Bradley A, Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically-induced skin tumors. Cell 74:813-822
21. 21. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T (1998) Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12:1121-1133
22. 22. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10:175-180
23. 23. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:931-936
24. 24. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
25. 25. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
26. 26. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206
27. 27. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378:206-208
28. 28. Jones SN, Sands AT, Hancock AR, Vogel H, Donehower LA, Linke SP, Wahl GM, Bradley A (1996) The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of mdm2. Proc Natl Acad Sci USA 93:14106-14111
29. 29. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE (1996) Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 10:836-850
30. 30. Nakamura T, Pichel JG, Williams-Simons L, Westphal H (1995) An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci USA 92:6142-6146
31. 31. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M (1997) Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 16:1381-1390
32. 32. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-4667
33. 33. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW (1996) The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85:1009-1023
34. 34. Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH (1996) Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early post-implantation development. Genes Dev 10:1835-1843
35. 35. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brcal/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11:1226-1241
36. 36. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12:191-194
37. 37. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810
38. 38. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11:1242-1252.
39. 39. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW (1997) Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16:298-302
40. 40. Lim DS, Hasty P (1996) A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 16:7133-7143
41. 41. Clarke AR, Cummings MC, Harrison DJ (1995) Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 11:1913-1920
42. 42. Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R (1997) Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet 17: 114-118
43. 43. Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P (1997) Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 16:397-401
44. -/- mice. Mol Cell Biol 18:4385-4390
45. 45. Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, Danska JS (1996) V(D)J recombination activates p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev 10:2038-2054
46. 46. Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T (1996) Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10:2055-2066
47. 47. Liao MJ, Zhang XX, Hill R, Gao J, Qumsiyeh MB, Nichols W, Van Dyke T (1998) No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol Cell Biol 18:3495-3501
48. 48. Nacht M, Jacks T (1998) V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ 9:131-138
49. 49. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P (1995) The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 11:181-190
50. 50. McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB (1998) Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16:2755-2766
51. 51. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, McDonnell TJ (1994) Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107-3112
52. 52. Blyth K, Terry A, O'Hara M, Baxter EW, Campbell M, Stewart M, Donehower LA, Onions DE, Neil JC, Cameron ER (1995) Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10:1717-1723
53. 53. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC (1998) p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 16:2965-2974
54. 54. Curtis DJ, Robb L, Strasser A, Begley CG (1997) The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. Oncogene 15:2975-2983
55. 55. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR (1996) Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-ras Ha, v-fos, or human transforming growth factor alpha. Cancer Res 56:4413-4423
56. 56. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG (1998) Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA 95:8858-8863